转移性乳腺癌患者监督下运动项目:PREFERABLE-EFFECT随机对照试验伴随的成本-效用分析
该成本-效用分析伴随跨国PREFERABLE-EFFECT随机对照试验开展,纳入357例转移性乳腺癌患者,比较9个月、每周两次监督下运动组与对照组(常规照护并补充一般活动建议与活动追踪器)。结果显示运动组QALY增益0.013(95%CI,-0.02至0.05),两种监督模式下总成本均低于对照组,在每QALY 20,000欧元支付意愿阈值下具有成本效用的概率分别为65%和91%。
要点
- 9个月监督下运动组较对照组获得0.013 QALY增益(95%CI,-0.02至0.05),未达统计学显著。
- 一对一监督模式每人运动项目成本为1,696欧元,一对四监督模式为609欧元。
- 在每QALY 20,000欧元阈值下,两种模式的成本效用概率分别为65%和91%。
核心结论
- 对转移性乳腺癌患者,运动可提高生活质量、降低费用,并可能具有成本效用;团体监督预计可带来更高的成本节约;这些积极结果可为监督下运动干预的报销提供参考。
研究设计与样本
- 该成本-效用分析伴随跨国PREFERABLE-EFFECT随机对照试验开展,在歐洲和澳大利亚的8个中心进行,纳入357例转移性乳腺癌患者,随机分配至9个月、每周两次监督下运动组或对照组(常规照护并补充一般活动建议与活动追踪器)。
- 成本采用自下而上法计算,其他医疗资源使用、生产力损失和生活质量通过各国适配的自报问卷收集;分析采用社会视角,时间范围为9个月;成本以2021年欧元收集和报告(€1=1.18美元)。
主要发现
- 与对照组相比,运动组在9个月期间获得0.013的质量调整生命年(QALY)增益(95%CI,-0.02至0.05)。
- 运动项目平均成本为每位患者一对一监督模式(情景1)1,696欧元、一对四监督模式(情景2)609欧元。
- 这些成本被医疗保健和生产力成本节约所抵消,平均总成本差异为情景1 -163欧元、情景2 -1,249欧元,均有利于运动组。
- 在每QALY 20,000欧元支付意愿阈值下,监督下运动具有成本效用的概率为情景1 65%、情景2 91%。
关键数值与推荐
- QALY增益:运动组较对照组0.013(95%CI,-0.02至0.05),9个月期间。
- 运动项目成本:一对一监督模式每人1,696欧元,一对四监督模式每人609欧元。
- 平均总成本差异:情景1 -163欧元、情景2 -1,249欧元,均有利于运动组。
- 成本效用概率:在每QALY 20,000欧元支付意愿阈值下,情景1为65%、情景2为91%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the cost utility of a 9-month supervised exercise program for patients with metastatic breast cancer (mBC), compared with control (usual care, supplemented with general activity advice and an activity tracker). Evidence on the cost-effectiveness of exercise for patients with mBC is essential for implementation in clinical practice and is currently lacking. METHODS: A cost-utility analysis was performed alongside the multinational PREFERABLE-EFFECT randomized controlled trial, conducted in 8 centers across Europe and Australia. Patients with mBC (N = 357) were randomly assigned to either a 9-month, twice-weekly, supervised exercise group (EG) or control group (CG). Costs of the exercise program were calculated through a bottom-up approach. Other health care resource use, productivity losses, and quality of life were collected using country-adapted, self-reported questionnaires. Analyses were conducted from a societal perspective with a time horizon of 9 months. Costs were collected and reported in 2021 Euros (€1 = $1.18 US dollars). RESULTS: Compared with the CG, EG resulted in a quality-adjusted life-year (QALY) gain of 0.013 (95% CI, -0.02 to 0.05) over a 9-month period. The mean costs of the exercise program were €1,696 per patient with one-on-one supervision (scenario 1) and €609 with one-on-four supervision (scenario 2). These costs were offset by savings in health care and productivity costs, resulting in mean total cost differences of -€163 (scenario 1) and -€1,249 (scenario 2) in favor of EG. The probability of supervised exercise being cost-effective was 65% in scenario 1 and 91% in scenario 2 at a willingness-to-pay threshold of €20,000 per QALY. CONCLUSION: Exercise for patients with mBC increases quality of life, decreases costs, and is likely to be cost-effective. Group-based supervision is expected to have even higher cost-savings. Our positive findings can inform reimbursement of supervised exercise interventions for patients with mBC.
引用
- Schouten AEM, Hiensch AE, Frederix GWJ, et al. Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial. J Clin Oncol. 2025. PMID: 39805062. doi:10.1200/JCO-24-01441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。